secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyant Bio, Inc. (—)
CIK:        0001349929
Form:       8-K
Filed at:   2023-02-03T23:59:59+00:00
Accession:  0001493152-23-003456
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vyant Bio cuts workforce, CEO and CSO depart; CFO takes over as company seeks sale or wind-down
--------------------------------------------------------------------------------

- Board approved Cash Preservation Plan on Jan 31, including a reduction in force to retain only core employees.
- Estimated severance and termination costs of ~$1.4M in Q1 and Q2 2023; reductions expected by end of February.
- CEO John Roberts and CSO Robert Fremeau step down effective Feb 3; CFO Andrew LaFrence appointed President and CEO.
- Company continues to explore strategic alternatives with LifeSci Capital, including sale, merger, or orderly wind-down.
- Cash and cash equivalents ~$8.4M as of Jan 31, 2023; pre-clinical/clinical programs delayed or deferred.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/0001493152-23-003456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-003456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer